Evidence Review
Bacillus coagulans for IBS and Digestive Symptoms
Bacillus coagulans has the deepest clinical evidence base among spore-forming probiotics, with multiple randomized controlled trials testing distinct commercial strains.
An early double-blind RCT (Hun, 2009; n=44) assigned IBS patients to B. coagulans GBI-30, 6086 at 1 billion CFU once daily or placebo for 8 weeks. The probiotic group showed statistically significant reductions in composite abdominal pain scores and bloating compared to placebo, with no serious adverse events reported [1]. This strain (sold under the name GanedenBC30) has since been used in dozens of functional foods and supplements.
A 2023 multicenter RCT by Majeed et al. (n=70) tested 2 billion spores per day of B. coagulans MTCC 5856 (LactoSpore) for 4 weeks in adults with functional gas and bloating [2]. Participants receiving the probiotic showed significantly better scores on the Gastrointestinal Symptom Rating Scale (GSRS) for indigestion and on global patient-reported evaluation compared to placebo. The between-group difference in GSRS indigestion scores was statistically significant (p<0.05), and the effect was consistent across both study sites in southern India.
A 2021 CONSORT-compliant prospective trial (PMID 33545934) evaluated B. coagulans LBSC over 80 days in IBS patients. Outcomes included improvements in stool consistency, abdominal pain frequency, bloating, and overall IBS-SSS (Severity Scoring System) scores compared to placebo, with no adverse safety signals.
Across these trials, effect sizes for B. coagulans on IBS symptoms are modest to moderate — meaningful for quality of life but not a replacement for dietary management. Strain specificity matters: GBI-30 6086 and MTCC 5856 are distinct organisms and may not be interchangeable.
Bacillus subtilis for Gut Symptoms and Immune Function
Garvey et al. (2022) conducted a 6-week RCT in 76 healthy adults supplementing with B. subtilis BS50 at 2 billion CFU daily [3]. Compared to placebo, BS50 increased the proportion of participants showing improvement in bloating, burping, and flatulence from baseline to week 6 (47.4% vs. 22.2%). Markers of intestinal permeability (lactulose:mannitol ratio) and clinical chemistry panels remained within normal ranges, supporting a favorable safety profile.
A distinct line of research focuses on immune modulation. Lefevre et al. (2015) randomized 100 seniors aged 60–74 to B. subtilis CU1 (2 billion spores daily) or placebo during a 24-day winter supplementation period followed by a washout [4]. Those taking the probiotic showed significantly elevated fecal and salivary secretory IgA concentrations — direct markers of mucosal immune activity — compared to placebo. The probiotic group also trended toward fewer days of common infectious disease symptoms during the study period, though this secondary endpoint did not reach significance in the small sample.
The sIgA finding is mechanistically plausible: Bacillus spores interact with Peyer's patches (gut immune tissue) during germination, stimulating dendritic cell activation and downstream B cell class switching to IgA production.
Bacillus clausii for Antibiotic-Associated Diarrhea
Bacillus clausii is uniquely positioned among probiotics because its natural poly-antibiotic resistance allows it to survive and function even when antibiotic courses are ongoing — a benefit few conventional probiotics share. Spores of commercial B. clausii strains (O/C, N/R, SIN, T) survive simulated gastric fluids for at least 120 minutes and have been recovered live in feces for up to 12 days post-dosing, with germination documented in the small intestine.
A 2024 RCT published in Scientific Reports (PMID 38494525; n not specified in abstract) tested high-dose liquid B. clausii spores in children with persistent diarrhea [5]. The treated group recovered 2 days faster than controls (p<0.05) and showed 1.5–1.6-fold greater reductions in stool frequency and mucosal symptoms. Immunological markers including IgA and cytokine profiles also improved significantly in the probiotic group, suggesting an immune-mediated mechanism alongside direct gut barrier effects.
Multiple earlier meta-analyses and RCTs (including PMID 30103531, a systematic review of B. clausii for acute pediatric diarrhea) show consistent benefits in reducing diarrhea duration, with an excellent long-term safety record across populations ranging from infants to the elderly.
Limitations
Most Bacillus probiotic trials are short (4–12 weeks), frequently industry-sponsored, and use proprietary strains that cannot be assumed to generalize to all commercial products. The beneficial effects seen in populations with active gut symptoms are generally larger than those in healthy adults, where improvements tend to be subtle.
Long-term gut colonization does not occur — Bacillus species are transient residents that clear within weeks of stopping supplementation. Whether this transient activity produces durable microbiome changes in the long term remains an open question with limited data. For individuals with healthy gut function, the practical benefit may be smaller than for those managing IBS, bloating, or post-antibiotic dysbiosis.
Overall, the evidence base for spore-based probiotics is more mechanistically coherent and reproducible than for many conventional probiotic categories, primarily because the survival advantage is objectively measurable, and the clinical trials — while not uniformly large — are generally well-controlled and consistent in direction of effect.